GZA Sint-Vincentius

The gastroenterology department at GZA Sint-Vincentius is conducting a study that compares two oral agents to improve symptoms and daily functioning in patients with Irritable Bowel Syndrome.

• Comparative efficacy of ebastine versus mebeverine
• Impact on health‑related quality of life
• Measurement of quality‑adjusted life years
• Patient‑reported outcome assessments

Results aim to guide clinicians toward the most effective symptom‑relief strategy for this functional bowel disorder.

Researchers at the site are evaluating a novel oral compound for patients with moderately to severely active ulcerative colitis, focusing on both endoscopic healing and clinical remission.

• Efficacy of ABX464 compared with placebo
• Endoscopic improvement as primary endpoint
• Sustained clinical remission during maintenance phase
• Safety and tolerability profile of the investigational drug

The study seeks to expand therapeutic options for a disease that significantly affects quality of life.

A multicentric investigation at GZA Sint-Vincentius examines the optimal timing of biological therapy after ileocolonic resection in patients with Crohn's disease who are at risk for postoperative recurrence.

• Systematic early initiation versus endoscopy‑driven initiation of therapy
• Postoperative endoscopic recurrence rates
• Role of risk factors in guiding treatment decisions
• Long‑term disease control and patient outcomes

Findings will inform strategies to prevent disease recurrence and improve surgical prognosis.